Neuropeptide Y Blood Levels Rise During Heart Attacks: A New Biomarker for Acute MI
Plasma neuropeptide Y levels were significantly elevated in acute myocardial infarction patients compared to controls, suggesting NPY as a potential biomarker for heart attack diagnosis and prognosis.
Quick Facts
What This Study Found
Plasma NPY was significantly elevated in acute myocardial infarction patients vs controls, with levels correlating with cardiac damage severity.
Key Numbers
128 acute MI cases and 62 controls; cases sub-grouped into SYNTAX ≤22, 23-32, and ≥33 categories.
How They Did This
Case-control study comparing plasma NPY levels between acute MI patients and matched healthy controls. Assessed correlation with cardiac injury markers and clinical outcomes.
Why This Research Matters
Rapid and accurate heart attack diagnosis saves lives. If NPY provides complementary diagnostic information beyond traditional markers like troponin, it could improve early detection and risk stratification.
The Bigger Picture
NPY reflects sympathetic nervous system activation during cardiac stress. Its elevation during heart attacks connects the neuro-peptide system to acute cardiovascular events, potentially informing both diagnosis and understanding of how the nervous system contributes to cardiac damage.
What This Study Doesn't Tell Us
Case-control design cannot prove causation. NPY elevation could reflect general stress rather than specific cardiac damage. Small sample size typical of biomarker discovery studies. Clinical utility requires validation in larger prospective studies.
Questions This Raises
- ?Does NPY add diagnostic value beyond troponin for early heart attack detection?
- ?Could NPY levels predict heart attack outcomes like mortality or heart failure?
- ?Would blocking NPY signaling during acute MI reduce cardiac damage?
Trust & Context
- Key Stat:
- NPY elevated in MI Plasma neuropeptide Y significantly higher in heart attack patients, correlating with cardiac damage severity
- Evidence Grade:
- Moderate evidence: well-designed case-control study with significant findings, but requires validation in larger prospective cohorts.
- Study Age:
- Published in 2024. Adds to evidence for NPY as a cardiovascular biomarker.
- Original Title:
- Role of plasma neuropeptide Y in acute myocardial infarction: a case-control study.
- Published In:
- BMC cardiovascular disorders, 24(1), 692 (2024)
- Authors:
- Zheng, Yan-Li, Lin, Hui-Li, Li, Yue-Ting, Li, Mei-Mei, Du, Jing-Ru, Wang, Wan-da, Wang, Yao-Guo, Cai, Yin-Lian
- Database ID:
- RPEP-09676
Evidence Hierarchy
Frequently Asked Questions
Why does NPY increase during heart attacks?
NPY is released by the sympathetic (fight-or-flight) nervous system during cardiac stress. A heart attack triggers massive sympathetic activation, releasing NPY into the bloodstream. The level of NPY may reflect the severity of the cardiac event.
Could NPY testing help diagnose heart attacks?
This study suggests NPY could be a useful complementary biomarker, but it needs validation in larger studies. Currently, troponin is the gold standard for heart attack diagnosis. NPY might add prognostic information about sympathetic stress and cardiac risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09676APA
Zheng, Yan-Li; Lin, Hui-Li; Li, Yue-Ting; Li, Mei-Mei; Du, Jing-Ru; Wang, Wan-da; Wang, Yao-Guo; Cai, Yin-Lian. (2024). Role of plasma neuropeptide Y in acute myocardial infarction: a case-control study.. BMC cardiovascular disorders, 24(1), 692. https://doi.org/10.1186/s12872-024-04373-1
MLA
Zheng, Yan-Li, et al. "Role of plasma neuropeptide Y in acute myocardial infarction: a case-control study.." BMC cardiovascular disorders, 2024. https://doi.org/10.1186/s12872-024-04373-1
RethinkPeptides
RethinkPeptides Research Database. "Role of plasma neuropeptide Y in acute myocardial infarction..." RPEP-09676. Retrieved from https://rethinkpeptides.com/research/zheng-2024-role-of-plasma-neuropeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.